BioSpace News Archive

ALR Technologies Inc. (“ALRT” or the “Company”)(OTCPINK: ALRT), the diabetes management company, has been approved for its common stock to be DWAC FAST and has submitted an application to upgrade the trading of its common stock to the OTCQB ® Venture Market. OTCQB Trading Application The Company is pleased to announce that it has applied to the OTC Markets Group Inc. to upgrade trading from the Pink Market to the OTCQB Venture Market.

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Heather Rowe Armstrong has joined the company as Vice President of Investor Relations and Corporate Communications.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call.

HemaTerra Technologies acquired Champion Healthcare Technologies in 2019 and is now rebranding the new entity as InVita Healthcare Technologies. The InVita brand combines industry-leading solutions for optimizing

The US Drug Watchdog says, “Five weeks ago a medical director at a top 50 US Metro Area hospital called us to tell us that surgical masks in his city were in short supply.

INmune Bio , Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced that management will present at the 32nd Annual Roth Conference at 8:30 a.m. (PT) on Tuesday, March 17, 2020

Amyloidosis Support Groups (ASG), the leading nonprofit volunteer organization providing support nationwide for those impacted by all types of amyloidosis, today announced that over 300 participants have joined the Amyloidosis Patient Registry and it is now available to the entire community.

Presented at The International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting, results from three pivotal, randomized, placebo-controlled trials assessing efficacy of Addyi in treating premenopausal women with Hypoactive Sexual Desire Disorder, or HSDD, show clear benefits in multiple areas of female sexual function in as early as 4 weeks and maintained for duration of treatment.

RightEye LLC, revealed the winner of its 2020 RightEye Impact Award, Dr. Neil Renaud of EagleEye Performance Vision in Holland, MI. Dr. Renaud will be honored for his dedication to improving his patients’ lives, at an awards ceremony on Friday March 13th at the EagleEye Performance offices.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020 , it has received proceeds of approximately $5.9 million as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants (the “Class B Warrants”).